factory Outlets for 8 Essential Amino Acids - Other Protected Amino Acids for Disulfide bond – Gentolex
factory Outlets for 8 Essential Amino Acids - Other Protected Amino Acids for Disulfide bond – Gentolex Detail:
Product Detail
|
NO |
Products |
CAS No |
Application |
Key Quality Indicator |
||||
|
Purity |
Isomer |
Specific impurity |
*Max1 |
Moisture |
||||
|
1 |
Fmoc-Cys(Acm)-OH |
86060-81-3 |
Disulfide bond |
≥99.0% |
≤0.1% |
≤0.1% |
≤0.2% |
≤1.0% |
|
2 |
Fmoc-Cys(Mmt)-OH |
177582-21-7 |
Disulfide bond |
≥98.0% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
3 |
Fmoc-Cys(4-allylbutyrate)-OH |
/ |
Disulfide bond |
≥98.0% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
4 |
Mpa(Trt)-OH |
27144-18-9 |
End of sequence |
≥99.5% |
/ |
≤0.1% |
≤0.2% |
≤1.0% |
|
5 |
Fmoc-Thr(tBu)-OL |
189337-28-8 |
Octreotide |
≥97.0% |
≤0.3% |
≤0.5% |
≤1.0% |
≤1.0% |
|
6 |
Fmoc-D-Arg(pbf)-OH |
187618-60-6 |
Desmopressin |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤2.0% |
|
7 |
Fmoc-Gly-Gly-OH |
35665-38-4 |
Bivalirudin |
≥99.5% |
/ |
≤0.1% |
≤0.2% |
≤1.0% |
|
8 |
Fmoc-Gly-Gly-Gly-OH |
170941-79-4 |
Terlipressin |
≥99.5% |
/ |
≤0.1% |
≤0.2% |
≤1.0% |
|
9 |
Fmoc-Gly-Gly-Gly-Gly-OH |
/ |
Bivalirudin |
≥99.5% |
/ |
≤0.1% |
≤0.2% |
≤1.0% |
|
10 |
Fmoc-Gly-Asp(tBu)-OH |
/ |
Bivalirudin |
≥99.5% |
/ |
≤0.15% |
≤0.2% |
≤1.0% |
|
11 |
Boc-Cys(Trt)-OH |
21947-98-8 |
End of sequence |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
12 |
Boc-Arg(pbf)-OH |
200124-22-7 |
End of sequence |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
13 |
Boc-Ala-OH |
15761-38-3 |
End of sequence |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
14 |
Boc-D-Phe-OH |
18942-49-9 |
End of sequence |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
15 |
Boc-Gly-OH |
4530-20-5 |
End of sequence |
≥99.5% |
/ |
≤0.1% |
≤0.2% |
≤1.0% |
|
16 |
Boc-Lys(Boc)-OH.DCHA |
15098-69-8 |
End of sequence |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
17 |
Boc-Ser(tBu)-OH |
7738-22-9 |
End of sequence |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
18 |
Boc-Thr(tBu)-OH |
13734-40-2 |
End of sequence |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
19 |
Boc-D-Ala-OH |
7764-95-6 |
End of sequence |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
20 |
Boc-Met-OH |
2488-15-5 |
End of sequence |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
21 |
Boc-Tyr(tBu)-OH |
47375-34-8 |
End of sequence |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
22 |
Boc-D-Arg(pdf)-OH |
187618-60-6 |
End of sequence |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
23 |
Boc-Asp(OtBu)-OH.DCHA |
1913/12/8 |
End of sequence |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
24 |
Fmoc-HomoArg(pbf)-OH |
1159680-21-3 |
Eptifibatide |
≥98.5% |
≤0.2% |
/ |
≤0.5% |
≤2.0% |
|
25 |
Fmoc-Asp-OtBu |
129460-09-9 |
Thymalfasin |
≥99.5% |
≤0.1% |
≤0.1% |
≤0.2% |
≤1.0% |
|
26 |
Fmoc-Tyr(Me)-OH |
77128-72-4 |
Carbetocin |
≥98.5% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
27 |
Fmoc-Orn(Boc)-OH |
109425-55-0 |
Atosiban Omnipressin Daptomycin |
≥99.5% |
≤0.1% |
≤0.1% |
≤0.2% |
≤2.0% |
|
28 |
Fmoc-D-Tyr(Et)-OH |
162502-65-0 |
Atosiban |
≥99.5% |
≤0.1% |
≤0.1% |
≤0.2% |
≤1.0% |
|
29 |
Fmoc-Asp(OAll)-OH |
146982-24-3 |
Melanotan |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
30 |
Ac-Nle-OH |
15891-49-3 |
Melanotan |
≥99.0% |
/ |
≤0.3% |
≤0.3% |
≤1.0% |
|
31 |
Fmoc-Nle-OH |
77284-32-3 |
Melanotan Afamelanotide |
≥99.0% |
/ |
≤0.3% |
≤0.3% |
≤1.0% |
|
32 |
Ac-Glu(OtBu)-OH |
84192-88-1 |
Argireline Acetyl octapeptide-3 |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
33 |
Ac-β-Ala-OH·DCHA |
/ |
Acetyl tetrapeptide-5 |
≥99.0% |
/ |
≤0.3% |
≤0.3% |
≤1.0% |
|
34 |
Fmoc-ß-Ala-OH |
35737-10-1 |
Acetyl tetrapeptide-5 |
≥99.5% |
/ |
≤0.1% |
≤0.2% |
≤1.0% |
|
35 |
Fmoc-Hyp(tBu)-OH |
122996-47-8 |
Icatibant |
≥98.0% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
36 |
Fmoc-Thi-OH |
130309-35-2 |
Icatibant |
≥98.0% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
37 |
Fmoc-D-Tic-OH |
130309-33-0 |
Icatibant |
≥98.0% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
38 |
Fmoc-Oic-OH |
130309-37-4 |
Icatibant |
≥98.0% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
39 |
Boc-Sar-OH |
13734-36-6 |
Saralasin |
≥98.0% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
40 |
Fmoc-Sar-OH |
77128-70-2 |
Saralasin |
≥98.0% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
41 |
Fmoc-Tyr(SO3Na)-OH.H2O |
106864-37-3 |
Sincalide |
≥98.0% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
42 |
Fmoc-D-Asp(OtBu)-OH |
112883-39-3 |
Daptomycin |
≥98.5% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
43 |
Ac-Ser(tBu)-OH |
77285-09-7 |
Afamelanotide |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
44 |
Boc-HomoCys(Trt)-OH |
201419-16-1 |
Depreotide |
≥98.0% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
45 |
Fmoc-HomoCys(Trt)-OH |
167015-23-8 |
Depreotide |
≥98.0% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
46 |
Fmoc-Dab-OH |
161420-87-7 |
Snake venom |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
*Max1 = Max Unknown Purity
Other Indicator:
- Acetic Acid: ≤0.02% (All Products)
- Ethyl Acetate: ≤0.5% (All Products)
- Alcohol: ≤0.5% (All Products)
- Max Unknow Impurity: Fmoc-Trp(Boc)-OH (143824-78-6) ≤0.3%; Others ≤0.2%
Product detail pictures:
Related Product Guide:
"Sincerity, Innovation, Rigorousness, and Efficiency" could be the persistent conception of our organization for your long-term to establish alongside one another with shoppers for mutual reciprocity and mutual benefit for factory Outlets for 8 Essential Amino Acids - Other Protected Amino Acids for Disulfide bond – Gentolex , The product will supply to all over the world, such as: France, Benin, Cyprus, With the development and enlargement of mass clients abroad, now we've set up cooperative relationships with many major brands. We've our own factory and also have many reliable and well-cooperated factories in the field. Adhering to the "quality first, customer first, We are provideing high-quality, low-cost items and first-class service to customers. We sincerely hope to establish business relationship with customers from all over the world on the basis of quality, mutually benefit. We welcome OEM projects and designs.
By Aaron from Brunei - 2017.05.02 11:33
This is a reputable company, they have a high level of business management, good quality product and service, every cooperation is assured and delighted!
By Joanna from UAE - 2017.01.28 18:53
